Clinical Trials Logo

Clinical Trial Summary

The purpose of this Phase 1 study is to determine if AMG 211 given as a continous intravenous (IV) infusion is safe and tolerable in adult participants that have advanced gastrointestinal adenocarcinoma. The study will be conducted in multiple sites and test increasing doses of AMG 211. The safety of participants will be monitored by intensive assessment of vital signs, electrocardiograms, physical examinations, and laboratory tests. Efficacy will be assessed by the usual imaging procedures and their interpretation.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT02291614
Study type Interventional
Source Amgen
Contact
Status Terminated
Phase Phase 1
Start date November 27, 2014
Completion date January 9, 2018